Tetra Bio-Pharma Files Patent Application to Protect PPP001
January 28 2019 - 6:30AM
Tetra Bio-Pharma
Inc (“
Tetra” or the
“
Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF),
a leader in cannabinoid-based drug discovery and development has
announced that it filed a patent application for its PPP001
drug product. Tetra’s research has led to a significant discovery
that has enabled the company to apply for patent protection.
Tetra's research demonstrated that the class II
medical device or pipe used to combust the PPP001 drug pellet
generates a unique composition of medicinal ingredients. This
composition is significantly different from that created when
heating the drug pellet in a vaporizer. The data demonstrated that
the drug produced by combustion is different from that of the vapor
and may partly explain the recognized efficacy of smoked cannabis.
The composition of the remaining chemicals was expected to be
different between smoke and vapor. This led the Corporation to
implement two separate drug development paths and allow Tetra
to commence developing second generation drugs for inhalation.
The patent covers methods of fabrication and
composition of matter. “This patent application, if granted, would
provide Tetra with full protection of its PPP001 prescription drug
product placing PPP001 in the same category as any other innovative
prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra
Bio-Pharma. “This will give Tetra a much longer period of
exclusivity. We recognize the inherent value of our intellectual
property and the necessity to seek appropriate patents, to the
extent possible, to protect our shareholders' investments in the
Company.”
Dr. Chamberland further stated, “In addition, we
are pleased to announce that Tetra Natural Health’s exclusive
distribution partner, Kombucha Baby Brewing Company, has advised us
that our Hemp Energy Drink will be made available in a number of
additional outlets in Ontario and Quebec in the not too distant
future. We are very encouraged by the reaction of the market since
its introduction in Q4 2018.”
About Tetra Bio-Pharma:Tetra Bio-Pharma
(TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health
Canada approved, and FDA reviewed, clinical program aimed at
bringing novel prescription drugs and treatments to patients and
their healthcare providers. The Company has several subsidiaries
engaged in the development of an advanced and growing pipeline of
Bio Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is focused on
providing rigorous scientific validation and safety data required
for inclusion into the existing bio pharma industry by regulators,
physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding: the anticipated benefits
of the Proposed Transaction for Tetra; completion and expected
timing of the Proposed Transaction; whether the terms of the
Proposed Transaction will be as described in this press release;
whether the Proposed Transaction will be successful; the receipt of
the approval of the TSXV in respect of the Proposed Transaction)
are forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of PPP001 and the
Hemp Energy Drink, the applicability of the discoveries made
therein, the successful and timely completion and uncertainties
related to the regulatory process including the applications for
Orphan Drug Designation, the timing of clinical trials, the timing
and outcomes of regulatory or intellectual property decisions and
other risks disclosed in the Company's public disclosure record on
file with the relevant securities regulatory authorities. Although
the Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. No definitive documentation has yet
been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
For
further information, please contact Tetra Bio-Pharma
Inc. |
Guy
Chamberland, Ph.D., |
Chief
Executive Officer and Chief Scientific Officer |
514-220-9225 |
Investors@tetrabiopharma.com |
|
|
Media
Contact |
|
Energi PR |
|
Carol Levine |
Stephanie Engel |
514-288-8500 ext.
226 |
416-425-9143 ext.
209 |
Carol.levine@energipr.com |
Stephanie.engel@energipr.com |
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Apr 2023 to Apr 2024